Elevated serum levels of vascular endothelial growth factor is effective as a marker for malnutrition and inflammation in patients with ovarian cancer

Watanabe,Takafumi; Shibata,Masahiko; Nishiyama,Hiroshi; Soeda,Shu; Furukawa,Shigenori; Gonda,Kenji; Takenoshita,Seiichi; Fujimori,Keiya

doi:10.3892/br.2013.54

Elevated serum levels of vascular endothelial growth factor is effective as a marker for malnutrition and inflammation in patients with ovarian cancer

Authors:
- Takafumi Watanabe
- Masahiko Shibata
- Hiroshi Nishiyama
- Shu Soeda
- Shigenori Furukawa
- Kenji Gonda
- Seiichi Takenoshita
- Keiya Fujimori
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Fukushima Medical University, Fukushima, Fukushima 960‑1295, Japan, Department of Tumor and Host Bioscience, Fukushima Medical University, Fukushima, Fukushima 960‑1295, Japan, Department of Organ Regulatory Surgery, Fukushima Medical University, Fukushima, Fukushima 960‑1295, Japan
Published online on: January 16, 2013 https://doi.org/10.3892/br.2013.54
Pages: 197-201

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vascular endothelial growth factor (VEGF) reportedly plays an important role in the progression of malignant neoplasms. In the present study, measured serum concentrations of VEGF were measured in patients with ovarian cancer and correlations with nutritional damage and chronic inflammation were analyzed. A significant increase in serum levels in patients compared to healthy volunteers was observed. Levels of VEGF were inversely correlated with serum concentrations of prealbumin, transferrin and retinol‑binding protein. VEGF levels were also correlated with serum levels of c‑reactive protein (CRP), an effective marker of inflammation. CRP levels were significantly elevated in patients with stage III and IV disease and inversely correlated with serum concentrations of total protein, prealbumin, transferrin and retinol‑binding protein. These results demonstrated that an increased production of VEGF correlated with nutritional impairment and inflammation.

View Figures

View References

1	Jacobs IJ and Menon U: Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 3:355–366. 2004. View Article : Google Scholar : PubMed/NCBI
2	Geva E and Jaffe RB: Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril. 74:429–438. 2000. View Article : Google Scholar : PubMed/NCBI
3	Goldman E: The growth of malignant disease in man and the lower animals with special reference to the vascular system. Proc R Soc Med. 1:1–13. 1908.PubMed/NCBI
4	Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995. View Article : Google Scholar : PubMed/NCBI
5	Senger DR, Galli SJ, Dvorak AM, et al: Tumor cell secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:983–985. 1983. View Article : Google Scholar
6	Ferrara N: Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res. 55:15–36. 2000.PubMed/NCBI
7	Terheyden P, Schrama D, Pedersen LO, et al: Longitudinal analysis of MART-1/HLA-A2-reactive T cells over the course of melanoma progression. Scand J Immunol. 58:566–571. 2003. View Article : Google Scholar : PubMed/NCBI
8	Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
9	Ostrand-Rosenberg S and Sinha P: Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 182:4499–4506. 2009. View Article : Google Scholar : PubMed/NCBI
10	Rubin H: Cancer cachexia: its correlations and causes. Proc Natl Acad Sci USA. 100:5384–5389. 2003. View Article : Google Scholar : PubMed/NCBI
11	Deans C and Wigmore SJ: Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 8:265–269. 2005. View Article : Google Scholar : PubMed/NCBI
12	Kajdaniuk D, Marek B, Foltyn W and Kos-Kudla B: Vascular endothelial growth factor (VEGF)-part 2: in endocrinology and oncology. Endocrinol Pol. 62:456–464. 2011.PubMed/NCBI
13	Sanz L, Ovejero VJ, Gonzalez JJ, et al: Mortality risk scales in esophagotomy for cancer: their usefulness in preoperative patients selection. Hepatogastroenterology. 53:869–873. 2006.PubMed/NCBI
14	Onate-Ocana LF, Aiello-Crocifoglio V, Gallardo-Rincon D, et al: Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol. 14:381–389. 2007. View Article : Google Scholar : PubMed/NCBI
15	Chua W, Charles KA, Baracos VE and Clarke SJ: Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Brit J Cancer. 104:1288–1295. 2011. View Article : Google Scholar : PubMed/NCBI
16	Cho H, Hur HW, Kim SW, et al: Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 58:15–23. 2009. View Article : Google Scholar : PubMed/NCBI
17	Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA and Markovic SN: Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res. 15:1931–1939. 2009. View Article : Google Scholar : PubMed/NCBI
18	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
19	Shibata M, Shimura T, Gonda K, Suzuki S, Nakamura I, Ohki S and Takenoshita S: Relationship of myeloid-derived suppressor cells (MDSC) and immune suppression, nutritional impairment, and inflammatory markers in patients with gastrointestinal cancer. 2012 ASCO Gastrointestinal Cancer Symposium: ASCO abs. 675,. 2012.
20	Ohki S, Shibata M, Gonda K, et al: Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoalbuminemia in patients with cancer. Oncol Rep. 28:453–458. 2012.PubMed/NCBI
21	Gabrilovich DI, Chen HL, Girgis KR, et al: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 2:1096–1103. 1996. View Article : Google Scholar : PubMed/NCBI
22	Menetrier-Caux C, Montmain G, Dieu MC, et al: Inhibition of the differentiation of dendritic cells from CD34+ progenitors by tumor cells: role of interleukin-6 and macrophage-colony-stimulating factor. Blood. 92:4778–4791. 1998.
23	Gabrilovich D, Ishida T, Oyama T, et al: Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 92:4150–4166. 1998.